New Two-Pronged attack on advanced cancers enters human testing

NCT ID NCT03972657

Recruiting now Disease control Sponsor: Regeneron Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study is testing a new experimental drug called REGN5678, which is designed to help the body's immune system find and attack cancer cells. It is being tested alone and in combination with an existing immunotherapy drug (cemiplimab) in patients with advanced prostate cancer or kidney cancer that has spread and stopped responding to standard treatments. The first goal is to find a safe dose, and then to see if the treatment can shrink tumors.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLEAR CELL RENAL CELL CARCINOMA (CCRCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Banner MD Anderson Cancer Center
RECRUITING

Gilbert, Arizona, 85234, United States
Columbia University - The Trustees of Columbia University in the City of New York
RECRUITING

New York, New York, 10032, United States
Emily Couric Clinical Cancer Center
RECRUITING

Charlottesville, Virginia, 22908, United States
Icahn School of Medicine at Mount Sinai
RECRUITING

New York, New York, 10029, United States
John Wayne Cancer Institute (JWCI)
RECRUITING

Santa Monica, California, 90404, United States
Lifespan Cancer Institute
RECRUITING

Providence, Rhode Island, 02903, United States
MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
Massachusetts General Hospital
RECRUITING

Boston, Massachusetts, 02114, United States
Mayo Clinic
RECRUITING

Phoenix, Arizona, 85054, United States
Mayo Clinic
RECRUITING

Rochester, Minnesota, 55905, United States
Mayo Clinic Jacksonville
RECRUITING

Jacksonville, Florida, 32224, United States
Moffitt Cancer Center - McKinley Drive
RECRUITING

Tampa, Florida, 33612, United States
Montefiore Medical Center
RECRUITING

New York, New York, 10461, United States
NYU Langone Health Perlmutter Cancer Center
RECRUITING

New York, New York, 10016, United States
Oregon Health & Science University (3485 S. Bond)
RECRUITING

Portland, Oregon, 97239, United States
Providence Portland Medical Center
WITHDRAWN

Portland, Oregon, 97213, United States
Sarah Cannon Research Institute (SCRI)
RECRUITING

Denver, Colorado, 80218, United States
Thomas Jefferson University Hospital
RECRUITING

Philadelphia, Pennsylvania, 19107, United States
University of Arizona
RECRUITING

Tucson, Arizona, 85724, United States
University of Rochester Medical Center (URMC) - Wilmot Cancer Institute (WCI) (James P. Wilmot Cancer Center) - Rochester
RECRUITING

Rochester, New York, 14642, United States
Yale University Hospital
RECRUITING

New Haven, Connecticut, 06510, United States

Conditions

Explore the condition pages connected to this study.

CLEAR CELL RENAL CELL CARCINOMA (CCRCC) METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)